NASDAQ:VRCA

Verrica Pharmaceuticals (VRCA) Stock Price, News & Analysis

Verrica Pharmaceuticals logo
$2.74 -0.14 (-4.86%)
Closing price 04:00 PM Eastern
Extended Trading
$2.79 +0.05 (+1.79%)
As of 04:35 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Verrica Pharmaceuticals Stock (NASDAQ:VRCA)

Advanced

Key Stats

Today's Range
$2.73
▼
$2.96
50-Day Range
$2.86
▼
$4.91
52-Week Range
$2.73
▼
$9.82
Volume
127,031 shs
Average Volume
86,267 shs
Market Capitalization
$47.07 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$12.67
Consensus Rating
Hold

Company Overview

Verrica Pharmaceuticals is a dermatology-focused biopharmaceutical company that develops and commercializes treatments for skin diseases. The company is based in West Chester, Pennsylvania, and its activities include both marketed products and investigational therapies.

Its FDA-approved product, YCANTH, is a topical cantharidin treatment for molluscum contagiosum in adults and children ages 2 and older. The treatment is applied by a healthcare professional.

Verrica is also developing therapies for other skin conditions. Its investigational pipeline includes VP-315, a peptide-based treatment being studied for basal cell carcinoma; it has not been approved for use.

AI Generated. May Contain Errors.

Verrica Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
40th Percentile Overall Score

VRCA MarketRank™: 
1.979180934115 of 5 stars

Verrica Pharmaceuticals scored higher than 40% of companies evaluated by MarketBeat, and ranked 627th out of 845 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Verrica Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on no strong buy ratings, 3 buy ratings, 1 hold rating, and 1 sell rating.

  • Upside Potential

    Verrica Pharmaceuticals has a consensus price target of $12.67, representing about 340.4% upside from its current price of $2.88.

  • Amount of Analyst Coverage

    Verrica Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.

  • Read more about Verrica Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Verrica Pharmaceuticals are expected to grow in the coming year, from ($2.25) to ($1.70) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Verrica Pharmaceuticals is -1.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Verrica Pharmaceuticals is -1.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Percentage of Shares Shorted

    3.02% of the float of Verrica Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Verrica Pharmaceuticals has a short interest ratio ("days to cover") of 4.58.
  • Change versus previous month

    Short interest in Verrica Pharmaceuticals has recently increased by 26.89%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Verrica Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Verrica Pharmaceuticals does not have a long track record of dividend growth.

  • News Sentiment

    Verrica Pharmaceuticals has a news sentiment score of -0.46. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.40 average news sentiment score of Healthcare companies.
  • Insider Buying vs. Insider Selling

    In the past three months, Verrica Pharmaceuticals insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    52.90% of the stock of Verrica Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    42.45% of the stock of Verrica Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Verrica Pharmaceuticals' insider trading history.
Receive VRCA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Verrica Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

VRCA Stock News Headlines

Verrica (VRCA) Q3 2026 Earnings Call Transcript
Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratings' latest research says 2026 could be very rough for some well-known stocks. A major shift now taking shape in the market could hit some of America's most-loved names hard. Weiss analysts have pinpointed five stocks they believe investors should steer clear of while it plays out.tc pixel
See More Headlines

VRCA Stock Analysis - Frequently Asked Questions

Verrica Pharmaceuticals' stock was trading at $8.31 at the beginning of 2026. Since then, VRCA stock has decreased by 65.4% and is now trading at $2.8760.

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) released its quarterly earnings results on Thursday, November, 12th. The company reported ($0.58) earnings per share for the quarter, missing analysts' consensus estimates of ($0.50) by $0.08. The company had revenue of $6.91 million for the quarter, compared to the consensus estimate of $6.20 million. Verrica Pharmaceuticals had a negative trailing twelve-month return on equity of 423.63% and a negative net margin of 189.23%.
Read the conference call transcript
.

Verrica Pharmaceuticals's stock reverse split before market open on Friday, July 25th 2025.A 1-10 reverse split was announced. The number of shares owned by shareholders was adjusted after the market closes on Thursday, July 24th 2025. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Verrica Pharmaceuticals (VRCA) raised $75 million in an initial public offering (IPO) on Friday, June 15th 2018. The company issued 5,000,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Jefferies and Cowen served as the underwriters for the IPO.

Top institutional investors of Verrica Pharmaceuticals include State Street Corp (0.17%) and Fifth Third Bancorp (0.16%). Insiders that own company stock include Paul B Manning, Perceptive Advisors Llc, Jayson Rieger, Ted White, David Zawitz, Christopher G Hayes, Joe Bonaccorso, John J Kirby and Noah L Rosenberg.
View institutional ownership trends
.

Shares of VRCA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Verrica Pharmaceuticals investors own include NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Iovance Biotherapeutics (IOVA), Rithm Capital (RITM), Energy Transfer (ET) and NIO (NIO).

Company Calendar

Last Earnings
11/12/2026
Today
11/20/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:VRCA
CIK
1660334
Fax
N/A
Employees
76
Year Founded
2013

Price Target and Rating

High Price Target
$17.00
Low Price Target
$9.00
Potential Upside/Downside
+362.3%
Consensus Rating
Hold
Rating Score (0-4)
2.40
Research Coverage
5 Analysts

Profitability

EPS (Trailing Twelve Months)
($2.22)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$17.89 million
Net Margins
-189.23%
Pretax Margin
-189.23%
Return on Equity
-423.63%
Return on Assets
-102.46%

Debt

Debt-to-Equity Ratio
0.18
Current Ratio
1.66
Quick Ratio
1.33

Sales & Book Value

Annual Sales
$35.58 million
Price / Sales
1.32
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($0.35) per share
Price / Book
-7.83

Miscellaneous

Outstanding Shares
17,180,000
Free Float
8,091,000
Market Cap
$47.07 million
Optionable
Optionable
Beta
1.69

Social Links

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

This page (NASDAQ:VRCA) was last updated on 11/20/2026 by MarketBeat.com Staff.
From Our Partners